ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0458

Drug Switching Due to Inefficacy in Rheumatoid Arthritis Patients Treated with Biological and Targeted Therapies. Daily Clinical Experience
Abstract Number: 0602

Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Co-Stimulation Pathways in Systemic Lupus Erythematosus
Abstract Number: 1037

Dual Energy Computed Tomography (DECT) Urate Volume Predicts Fulfillment of Gout Remission After Two Years of Intensive Urate-Lowering Therapy
Abstract Number: 1770

Dual Inhibition of TNF-α and OX40L on Synovial Inflammation and Osteoclastogenesis in Rheumatoid Arthritis
Abstract Number: 1812

Duloxetine and the Risk for Cardiovascular Events in US Veterans with Non-Cancer Pain
Abstract Number: 0856

Dupilumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Abstract Number: 0499

Durability of Response Among Patients with Psoriatic Arthritis (PsA) Using Biological or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/Spondyloarthritis Registry
Abstract Number: 1750

Dysregulated NUB1 and Neddylation Enhances Rheumatoid Arthritis Fibroblast-Like Synoviocyte Inflammatory Responses
Abstract Number: 0266

E-selectin, ICAM-1 and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases
Abstract Number: 1853

Each Joint in a 28 Joint Count Is More Likely to Be Affected by Deformity/Limited Motion Than by Swelling in Rheumatoid Arthritis Patients with Long Disease Duration: Deformity/Limited Motion Should Be Included in Joint Counts Performed in Routine Care
Abstract Number: L08

Early Clinical Development of CIT-013, a First in Class NETosis Inhibitor, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers Demonstrating Potent Inhibition of LPS Induced Neutrophil Extracellular Trap Formation
Abstract Number: 0853

Early Experience with Avacopan for ANCA-Associated Vasculitis in a Large Integrated Healthcare System
Abstract Number: 1490

Early Experience with SGLT2i in Systemic Lupus Erythematosus
Abstract Number: 1424

Early Fatigue Improvement with Guselkumab Associates with Longer Term Disease Control in Patients with Active Psoriatic Arthritis Reporting Substantial Fatigue: Post Hoc Analyses of a Sub-Population of a Phase 3, Randomized, Controlled Trial of Guselkumab in Biologic-Naïve Patients
Abstract Number: 2228

Early Improvement in 3 Visual Analogue Scale (3VAS)/4VAS Predicts Reduced Rates of Radiographic Change in Bio-naive Active Psoriatic Arthritis Patients Receiving Guselkumab Treatment

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].